Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor-Reference-Cited by-同舟云学术

Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor

Published:2024-05-29 Issue:6 Volume:14 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Shi Zi‐Yang¹^ORCID,Fang Ying¹,Xu Peng‐Peng¹,Yi Hong‐Mei²,Li Jian‐Feng¹,Dong Yan¹,Zhu Yue¹,Liu Meng‐Ke¹,Fu Di¹,Wang Shuo¹,Shi Qing¹,Shen Rong¹,Zhong Hui‐Juan¹,Wang Chao‐Fu²,Cheng Shu¹,Wang Li¹³,Liu Feng¹,Zhao Wei‐Li¹³^ORCID

Affiliation:

1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

2. Department of Pathology, Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

3. Pôle de Recherches Sino‐Français en Science du Vivant et Génomique Laboratory of Molecular Pathology Shanghai China

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.1691

Reference10 articles.

1. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

2. cola: an R/Bioconductor package for consensus partitioning through a general framework

3. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

4. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma

5. Clinical implications of T cell exhaustion for cancer immunotherapy